Board of Directors

Kenneth A. Charhut

Kenneth Charhut has two decades of senior management experience in the medical device and biotechnology industries, with significant early stage expertise. Mr. Charhut currently serves as President & CEO of Orqis Medical, where he also serves on the Board of Directors. He is a founding member of Orqis Medical and led product development successfully advancing from product concept to approved clinical trials in 18 months. He secured $85 million in start-up capital, developed all corporate infrastructure programs, and formed the company’s Scientific Advisory Board, comprised of world-renowned thought leaders. Prior to joining Orqis Medical, Mr. Charhut spent over 16 years contributing to the growth and success of Baxter Healthcare Corporation. While at Baxter, Mr. Charhut served as President of the Bentley Division, directed new business initiatives for Baxter’s Cardiovascular Surgery Division, and spent four years in Japan as Managing Director of the Baxter’s Cardiovascular Division. While in Japan, Mr. Charhut also served as the Chairman of the American Chamber of Commerce in Japan’s Medical Device sector. Prior to his duties in Japan, he held positions managing Baxter’s pharmacy automation business and with the General Electric Company. Mr. Charhut earned a BSME degree from Cornell University and an MBA from the University of Chicago. He currently is a Board Member of the Southern California Biomedical Council and is associated with many local and national medical device organizations.

Jeani Delagardelle

Jeani Delagardelle is Managing Director of New Leaf Venture Partners, a healthcare technology fund established in August 2005 by the healthcare technology partners of the Sprout Group. Ms. Delagardelle joined Sprout in August 2000 and became General Partner in July 2001. Previously, she was General Partner at Weiss, Peck & Greer Venture Partners focused on healthcare investments. Before joining Weiss, Peck & Greer, Ms. Delagardelle spent 15 years in senior marketing, sales, business development and general manager positions in the healthcare industry, including serving as Vice President of Global Marketing for Target Therapeutics (acquired by Boston Scientific for $1.1 billion) and several senior management roles in the Medi-tech division of Boston Scientific. Ms. Delagardelle also served as Director of Business Operations for Roche Laboratories and Director of Global Marketing for Cell Pro, Inc. Ms. Delagardelle serves on the Board of Directors of Access Closure Inc., Aspire, Direct Flow Medical, Intrinsic Therapeutics, ReShape Medical, Spiration Inc., Visiogen, and World Heart. She holds an MBA from the University of California at Irvine and an A.B. from Occidental College.

Bill Murray

Bill Murray has over 20 years of leadership and executive experience in medical device and life science companies. He is currently the President and CEO of ReShape Medical, Inc. Prior to ReShape, Mr. Murray held executive positions at several highly successful medical companies, including President of the Molecular Biology Division of Applied Biosystems, Group President of Respiratory Technologies at Viasys Healthcare, and President of the Pacemaker business at Medtronic. Mr. Murray also ran Cardiac Rhythm Management Business Development, the Electrophysiology Systems Business, and the Functional Diagnostic Business for Medtronic. Prior to running these businesses, he had responsibility for engineering, development and project management of a number of implantable pacing systems. Mr. Murray holds a Bachelor of Science in Electrical Engineering from the University of Florida and has served on the Board of Directors of Zinectics Medical, Innovatus Ventures, and ReShape Medical.

David Milne

David Milne has over 20 years of operating experience leading therapeutic and diagnostic medical technology corporations and substantive venture capital and investment experience. Mr. Milne is currently a Managing Partner at SV Life Sciences (SVLS) which now has five funds with current committed capital of approximately $1.6 billion. Prior to joining SVLS, Mr. Milne held the position of Vice President of Corporate Business Development at Boston Scientific Corporation and was responsible for over 50 transactions totaling nearly $2 billion in acquisitions, equity investments and development partnerships. Mr. Milne also held executive level positions in Marketing, Corporate Planning, and Sales with Boston Scientific Cardiology, Becton Dickinson and Parker Laboratories. Mr. Milne holds an MBA from New York University and a BS in Biochemistry from Rutgers University. He serves on the Board of Directors of Aquesys, CardioMind, EBR, Entellus, Mindframe, Osteolign, ReShape, Sadra, Spinal Kinetics and TransEnterix.

Casey Tansey

Casey Tansey has venture investment experience and over 25 years of entrepreneurial, early stage medical device and seasoned operating experience. Mr. Tansey has served as General Partner at US Venture Partners (USVP) since April 2005. At USVP, Mr. Tansey focuses on the trend toward miniaturization of devices and the development of minimally-invasive innovations and disruptive technologies. He is a veteran of the medical device industry and prior to joining USVP, served as the CEO and President of Epicor Medical from 2001 to 2004. Mr. Tansey and his dedicated team pioneered a minimally-invasive treatment for atrial fibrillation and Mr. Tansey led Epicor’s acquisition by St. Jude Medical. Mr. Tansey also was CEO and President of Heartport, a public company that helped pioneer minimally-invasive cardiac surgery and now is a Johnson & Johnson company. Mr. Tansey also held various sales and marketing positions with Baxter Edward’s Cardiovascular Division for nearly ten years, launching innovative heart valve products that have grown to be market leaders. Mr. Tansey holds a B.S. and M.B.A. from the College of Notre Dame in Belmont, CA. He serves as the Chairman of the Board of Directors of the World Heart Foundation, an organization dedicated to advancing humanitarian efforts in heart surgery worldwide through education and collaboration and currently serves on the Board of Directors for ApniCure, CardioKinetix, Devax, Inspire Medical, Intuity Medical, Nanostim, SentreHEART and Sinexus

George Wallace

George Wallace is a veteran corporate executive and founder of many successful companies. Mr. Wallace currently is Managing General Partner for Intersect Partners LLC. Intersect Partners was formed as a research incubator and investment vehicle dedicated to advancing and founding medical device companies focused on solutions to large unmet medical needs. Intersect Partners founded, financed and managed ReShape Medical Inc. until early 2008 and Mr. Wallace remains on ReShape Medical’s Board of Directors. Intersect Partners also founded and currently manages MindFrame Inc., focused on less invasive treatments for ischemic stroke, and Altura Interventional Inc., a company dedicated to the treatment of aneurysm in the vascular system. Prior to Intersect Partners, Mr. Wallace co-founded and managed four companies, Sub-Q Inc., Micro Therapeutics Inc., TranS1 Inc. and ReShape Medical Inc. Mr. Wallace also served as General Manager of the Applied Vascular and Urology Divisions of Applied Medical Resources, Vice President of Marketing and Sales for Vaser Inc., and held various positions at Edwards Laboratories (a division of American Hospital Supply, which became Baxter International and now Edwards Lifesciences). Mr. Wallace holds a Bachelor of Science in Marketing from Arizona State University.

Andrew Cragg, MD

Dr. Cragg is a co-founder and board observer of ReShape Medical Inc. He is currently the co-founder and Managing Partner of Intersect Partners, LLC, a medical device incubator with offices in San Clemente and Minneapolis. He is also a Clinical Professor of Radiology at the University of Minnesota.

In addition to ReShape, Dr. Cragg has previously co-founded numerous medical companies including MicroTherapeutics, SubQ, TranS1, Mindframe and Altura Interventional. He holds over 100 issued and published US patents for novel technology in a wide range of medical fields and applications including vascular stents, aortic endografts, stroke therapy, spinal implants and bariatric devices.